Literature DB >> 16410800

Differential susceptibility to TRAIL of normal versus malignant human urothelial cells.

L P Steele1, N T Georgopoulos, J Southgate, P J Selby, L K Trejdosiewicz.   

Abstract

Comparing normal human urothelial (NHU) cells to a panel of six representative urothelial cell carcinoma (UCC)-derived cell lines, we showed that while TRAIL receptor expression patterns were similar, susceptibility to soluble recombinant crosslinked TRAIL fell into three categories. 4/6 carcinoma lines were sensitive, undergoing rapid and extensive death; NHU and 253J cells were partially resistant and HT1376 cells, like normal fibroblasts, were refractory. Both normal and malignant urothelial cells underwent apoptosis via the same caspase-8/9-mediated mechanism. Rapid receptor downregulation was a mechanism for evasion by some UCC cells. TRAIL resistance in malignant urothelial cells was partially dependent on FLIP(L) and was differentially mediated by p38(MAPK), whereas in normal cells, resistance was mediated by NF-kappaB. Importantly, extensive killing of UCC cells could be induced using noncrosslinked TRAIL after prolonged exposure, with no damage to their homologous, normal urothelial cell counterparts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410800     DOI: 10.1038/sj.cdd.4401846

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  11 in total

1.  8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Authors:  Ylermi Soini; Kirsi-Maria Haapasaari; Markku H Vaarala; Taina Turpeenniemi-Hujanen; V Kärjä; Peeter Karihtala
Journal:  Int J Clin Exp Pathol       Date:  2011-03-02

2.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

3.  SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.

Authors:  J Y Liu; Q H Zeng; P G Cao; D Xie; F Yang; L Y He; Y B Dai; J J Li; X M Liu; H L Zeng; X J Fan; L Liu; Y X Zhu; L Gong; Y Cheng; J D Zhou; J Hu; H Bo; Z Z Xu; K Cao
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

Review 4.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

5.  Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Authors:  Anirban P Mitra; Vincenzo Pagliarulo; Dongyun Yang; Frederic M Waldman; Ram H Datar; Donald G Skinner; Susan Groshen; Richard J Cote
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

6.  Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

Authors:  B Chopra; N T Georgopoulos; A Nicholl; J Hinley; M B Oleksiewicz; J Southgate
Journal:  Cell Prolif       Date:  2009-07-10       Impact factor: 6.831

7.  c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells.

Authors:  Travis W Day; Su Huang; Ahmad R Safa
Journal:  Biochem Pharmacol       Date:  2008-09-17       Impact factor: 5.858

8.  The role of c-FLIP splice variants in urothelial tumours.

Authors:  F Ewald; N Ueffing; L Brockmann; C Hader; T Telieps; M Schuster; W A Schulz; I Schmitz
Journal:  Cell Death Dis       Date:  2011-12-22       Impact factor: 8.469

9.  The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.

Authors:  Marie-Laure Plissonnier; Sylvie Fauconnet; Hugues Bittard; Isabelle Lascombe
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

10.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Yongming Li; Jiqin Lian; Theodore S Lawrence; Liang Xu
Journal:  BMC Cancer       Date:  2009-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.